Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients

Diagnostic Pathology

Rafal Matkowski²  Cyprian Kozyra³  Marek Leskiewicz³  Agnieszka Halon⁴  Marcin Zietek¹  Piotr Donizy⁴ 

[1] Lower Silesian Oncology Centre, pl. Hirszfelda 12, Wroclaw, 53-413, Poland;Department of Oncology and Division of Surgical Oncology, Wroclaw Medical University, pl. Hirszfelda 12, Wroclaw, 53-413, Poland;Department of Statistics, Wroclaw University of Economics, Komandorska 118-120, Wroclaw, 53-345, Poland;Department of Pathomorphology and Oncological Cytology, Wroclaw Medical University, Borowska 213, Wroclaw, 50-556, Poland

关键词: Immunohistochemistry;    Melanoma;    Prognosis;    ALCAM;   

Others  :  1219360
DOI  :  10.1186/s13000-015-0331-z

 received in 2014-09-25, accepted in 2015-06-17,  发布年份 2015

【 摘 要 】

Background

ALCAM (activated leukocyte cell adhesion molecule, CD166, MEMD) is a transmembrane protein of immunoglobulin superfamily (Ig-SF) and plays an important role in human malignant melanoma progression and formation of locoregional and distant metastases. The study using melanoma cell lines showed that overexpression of ALCAM is directly related with the increase of cytoaggregation and the ability to form cell nests. The aim of the study was to assess the expression and intracellular localization of ALCAM in primary skin melanomas and metastatic lesions from regional lymph nodes. Also, prognostic significance of ALCAM expression in primary tumor cells and metastatic lesion cells was evaluated in the context of 5-year observation.

Methods

Formalin-fixed paraffin-embedded tissue specimens from 104 primary cutaneous melanomas and 16 regional lymph nodes metastases were studied for the expression of ALCAM measured by immunohistochemistry.

Results

We demonstrate that high ALCAM expression in primary melanoma cells (IRS ≥8) is strongly correlated with unfavorable prognosis as compared with patients with lower ALCAM immunoreactivity in tumor compartment as regards cancer specific overall survival (CSOS) (P = 0.001) and disease free survival (DFS) (P < 0.001). Additionally lower ALCAM immunoreactivity in nodal metastatic foci was significantly statistically correlated with deeper melanoma invasion in the primary tumor according to Clark scale (P = 0.032). It was also found that decreased ALCAM expression (IRS <8) in nodal metastases shows a trend related with a correlation with shorter cancer specific overall survival (P = 0.083). Statistically significant correlations were also demonstrated between the presence of ulceration and decreased intensity of lymphocytic inflammatory infiltration and a high percentage of ALCAM-positive cells (P = 0.035, P = 0.01, respectively).

Conclusions

High ALCAM expression in melanoma cells of the primary tumor can be used as a marker of negative outcome and may indicate a more invasive phenotype of cancer cells, which would require a more intensive therapeutic strategy. Low expression of ALCAM in regional lymph node metastases is a feature associated with unfavorable prognosis in patients with cutaneous melanoma. Our study is the first one to evaluate the effect of increased ALCAM expression on long-term survival in melanoma patients.

【 授权许可】

   
2015 Donizy et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Gordon PR, Mansur CP, Gilchrest BA. Regulation of human melanocyte growth, dendricity, and melanization by keratinocyte derived factors. J Invest Dermatol. 1989; 92:565-72.
• [2]Hedley SJ, Wagner M, Bielby S, Smith-Thomas L, Gawkrodger DJ, MacNeil S. The influence of extracellular matrix proteins on cutaneous and uveal melanocytes. Pigment Cell Res. 1997; 10:54-9.
• [3]Jimbow K, Quevedo WC, Fitzpatrick TB, Szabo G. Some aspects of melanin biology: 1950–1975. J Investig Dermatol. 1976; 67:72-89.
• [4]Haass NK, Smalley KS, Li L, Herlyn M. Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res. 2005; 18:150-9.
• [5]Seline PC, Norris DA, Horikawa T, Fujita M, Middleton MH, Morelli JG. Expression of E and P-cadherin by melanoma cells decreases in progressive melanomas and following ultraviolet radiation. J Invest Dermatol. 1996; 106:1320-4.
• [6]Smalley KS, Brafford P, Haass NK, Brandner JM, Brown E, Herlyn M. Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am J Pathol. 2005; 166:1541-54.
• [7]Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Molecular plasticity of human melanoma cells. Oncogene. 2003; 22:3070-5.
• [8]Balzer EM, Konstantopoulos K. Intercellular adhesion: mechanisms for growth and metastasis of epithelial cancers. Wiley Interdiscip Rev Syst Biol Med. 2012; 4:171-81.
• [9]van Kempen LC, van den Oord JJ, van Muijen GN, Weidle UH, Bloemers HP, Swart GW. Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol. 2000; 156:769-74.
• [10]Bowen MA, Patel DD, Li X, Modrell B, Malacko AR, Wang WC, Marquardt H, Neubauer M, Pesando JM, Francke U, Hayens BF, Aruffo A. Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med. 1995; 181:2213-20.
• [11]Lehmann JM, Riethmuller G, Johnson JP. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci U S A. 1989; 86:9891-5.
• [12]van Kempen LC, Meier F, Egeblad M, Kersten-Niessen MJ, Garbe C, Weidle UH, Van Muijen GN, Herlyn M, Bloemers HP, Swart GW. Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasis. J Invest Dermatol. 2004; 122:1293-301.
• [13]Patel DD, Wee SF, Whichard LP, Bowen MA, Pesando JM, Aruffo A, Haynes BF. Identification and characterization of a 100-kD ligand for CD6 on human thymic epithelial cells. J Exp Med. 1995; 181:1563-8.
• [14]Degen WG, van Kempen LC, Gijzen EG, van Groningen JJ, van Kooyk Y, Bloemers HP, Swart GW. MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). Am J Pathol. 1998; 152:805-13.
• [15]Ofori-Acquah SF, King JA. Activated leukocyte cell adhesion molecule: a new paradox in cancer. Transl Res. 2008; 151:122-8.
• [16]Zhang G, Slaughter C, Humphries EH. v-rel Induces ectopic expression of an adhesion molecule, DM-GRASP, during B-lymphoma development. Mol Cell Biol. 1995; 15:1806-16.
• [17]Lunter PC, van Kilsdonk JW, van Beek H, Cornelissen IM, Bergers M, Willems PH, van Muijen GN, Swart GW. Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity. Cancer Res. 2005; 65:8801-8.
• [18]Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987; 8:138-40.
• [19]Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, Tahan SR. Increased expression of stem cell markers in malignant melanoma. Mod Pathol. 2007; 20:102-7.
• [20]Swart GW, Lunter PC, Kilsdonk JW, Kempen LC. Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration? Cancer Metastasis Rev. 2005; 24:223-36.
• [21]Swart GW. Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol. 2002; 81:313-21.